Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04332861 · ClinicalTrials.gov registry record
Evaluation of Infection in Obstructing Urolithiasis
A clinical trial of Sepsis and Infection, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 477
- Enrollment target
- 2
- Study locations
NCT04332861: Completed study of Sepsis and Infection, sponsored by University of Texas Southwestern Medical Center.
NCT04332861 is a study of Sepsis and Infection that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 477 participants, below the 6,559-participant average among 90 other Sepsis trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04332861, a study of Sepsis and Infection, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 477 participants
- Enrollment target
- 2
- Study locations
Study Summary
Obstructing urolithiasis can be life-threatening in the setting of urinary tract infection. The purpose of this study is to identify and validate risk factors and markers for the presence of infection and development of sepsis among patients with obstructing urolithiasis.
Primary Outcome
Urinary tract infection, defined as a positive urine culture
Conditions Studied
Interventions
- OTHER Initial clinical and laboratory evaluation
Study Locations (2)
Texas
- Parkland Memorial Hospital - Dallas
- UT Southwestern Medical Center Clements University Hospital - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 477 participants |
| Start Date | 2019-09-03 |
| Est. Completion | 2020-07-28 |
What the finished NCT04332861 record still lists
NCT04332861 is an observational study that tracks outcomes without assigning an intervention. The registered 477 participants enrollment target is mid-sized for trials with a published cap, below the 6,559-participant average among 90 other Sepsis trials with a reported enrollment target (93% lower).
The record links to 5 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Initial clinical and laboratory evaluation is the first listed.
NCT04332861 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04332861 about?
NCT04332861 is a clinical study titled "Evaluation of Infection in Obstructing Urolithiasis". Obstructing urolithiasis can be life-threatening in the setting of urinary tract infection. The purpose of this study is to identify and validate risk factors and markers for the presence of infection and development of sepsis among patients with obstructing urolithiasis.
What is the current status of trial NCT04332861?
This trial is currently completed. The enrollment target is 477 participants. The study started on 2019-09-03. Estimated completion is 2020-07-28.
What conditions does trial NCT04332861 study?
This clinical trial studies the following conditions: Sepsis, Infection, Kidney Stone, Kidney Calculi, Urinary Tract Obstruction.
What interventions are being tested in trial NCT04332861?
The interventions under investigation include: Initial clinical and laboratory evaluation (OTHER).
Who is sponsoring clinical trial NCT04332861?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04332861 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04332861's enrollment target sits among peer trials
477 26th of 90 higher than 65 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03911700 · 477 participants · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
- NCT06997497 · 477 participants · Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- NCT05446272 · 478 participants · NA
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
- NCT06172296 · 478 participants · Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI